A multidistrict litigation (MDL) to coordinate pretrial proceedings for all pending and future GranuFlo lawsuits has been created in Massachusetts, a federal judicial panel ruled in March.

The order released on March 29, 2013 by the Judicial Panel on Multidistrict Litigation (JPML) stated that all claims will be consolidated in the U.S. District Court, District of Massachusetts on the grounds that the actions filed over GranuFlo and NaturaLyte are factually similar.

Plaintiffs in GranuFlo and NaturaLyte lawsuits allege that use of the acid concentrates during dialysis treatments may lead to the following injuries within the first 48 hours:

  • sudden cardiac death
  • cardiovascular death
  • cardiopulmonary arrest
  • other catastrophic heart injuries
  • heart attack

Fresenius USA Voices Support for GranuFlo Lawsuit MDL in Massachusetts

Prior to this ruling, Fresenius USA had previously voiced its support for the creation of an MDL in Massachusetts, where the company is headquartered. On Jan. 3, 2013, the defendant in GranuFlo lawsuits publicly backed a petition to do so, which would impact the 11 claims pending in federal court at that time.

Given the fact that Fresenius is located in Waltham, Mass., the proximity to witnesses and documentary evidence will also be found there, the JPML said in its Order to centralize the actions filed against the company. Before deciding on Massachusetts, the judicial panel considered Mississippi, California and New Jersey as possible locations for an MDL.

The creation of the MDL for GranuFlo lawsuits was announced almost a year after the U.S. Food and Drug Administration (FDA) issued a NaturaLyte and GranuFlo recall in July 2012. The agency categorized the recall as Class I, which is the most serious type of recall only issued when there is determined to be a high likelihood that the product could lead to severe side effects and/or death.

Since the NaturaLyte GranuFlo recall, the FDA has vowed to continue its investigation of the drug’s safety and effectiveness in neutralizing acid build-up during dialysis treatments.  The agency is also investigating Fresenius USA for its hesitance in warning health care providers about the side effects associated with GranuFlo.

GranuFlo lawsuits have already uncovered the details of an internal company memo sent Nov. 4, 2011 that warned of 900 deaths stemming from GranuFlo use.

Considering a GranuFlo Lawsuit? Contact Us Today.

If you or a loved one used GranuFlo or NaturaLyte during a dialysis treatment and suffered a heart attack, sudden cardiac death, cardiopulmonary arrest or other life-threatening cardiovascular injuries, you may be eligible to file a claim against the manufacturer. Call an attorney at Bernstein Liebhard LLP to learn more about GranuFlo lawsuits at (877) 779-1414.

Published April 3, 2013 by